From cost containment to supply resilience: Japan’s evolving policy architecture for generic medicines

Generic medicines policy has long been framed around access and cost containment, but persistent shortages have made continuity of supply an equally pressing concern. This article examines how stable supply has entered Japan’s drug-pricing policy for generic medicines, focusing on four components of the FY2026 drug-pricing reform: minimum prices, basic medicines, unprofitable-product repricing, and the stable-supply manufacturer evaluation. Drawing on official Ministry of Health, Labour and Welfare and Central Social Insurance Medical Council documents, the study distinguishes routine supply sustainability — maintaining production under normal operating conditions — from disruption resilience, examined through four dimensions: dependence, substitutability, inventory, and time to recover. Each measure is assessed at three functional levels: recognition of a vulnerability, support for a supply condition, and secured capacity. All four measures support routine supply sustainability. Only two extend further. Unprofitable-product repricing recognizes difficulty in securing alternative supply, and the manufacturer evaluation rewards additional supply when another company’s product is subject to restricted or suspended shipment. None secures replacement capacity, inventory, or recovery time in advance. The article describes this development as resilience-aware pricing, distinguishes it from resilience procurement, and argues that the connection between pricing measures and Japan’s separate supply-security framework is now the central design question.

Authors

Institutions

Publication Details

Journal
Journal of Generic Medicines The Business Journal for the Generic Medicines Sector
Published
2026-11-12
DOI
https://doi.org/10.1177/17411343261508671
Primary Topic
Pharmaceutical Economics and Policy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

From cost containment to supply resilience: Japan’s evolving policy architecture for generic medicines

Hirohisa Shimura
Journal of Generic Medicines The Business Journal for the Generic Medicines Sector
Pharmaceutical Economics and Policy
article

From cost containment to supply resilience: Japan’s evolving policy architecture for generic medicines

Hirohisa Shimura
article en

Abstract

Generic medicines policy has long been framed around access and cost containment, but persistent shortages have made continuity of supply an equally pressing concern. This article examines how stable supply has entered Japan’s drug-pricing policy for generic medicines, focusing on four components of the FY2026 drug-pricing reform: minimum prices, basic medicines, unprofitable-product repricing, and the stable-supply manufacturer evaluation. Drawing on official Ministry of Health, Labour and Welfare and Central Social Insurance Medical Council documents, the study distinguishes routine supply sustainability — maintaining production under normal operating conditions — from disruption resilience, examined through four dimensions: dependence, substitutability, inventory, and time to recover. Each measure is assessed at three functional levels: recognition of a vulnerability, support for a supply condition, and secured capacity. All four measures support routine supply sustainability. Only two extend further. Unprofitable-product repricing recognizes difficulty in securing alternative supply, and the manufacturer evaluation rewards additional supply when another company’s product is subject to restricted or suspended shipment. None secures replacement capacity, inventory, or recovery time in advance. The article describes this development as resilience-aware pricing, distinguishes it from resilience procurement, and argues that the connection between pricing measures and Japan’s separate supply-security framework is now the central design question.

Journal of Generic Medicines The Business Journal for the Generic Medicines Sector
Soka University (JP)
Pharmaceutical Economics and Policy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon